Contract Research Organization (CRO) Services Market

Contract Research Organization (CRO) Services Market by Type (Early phase, Clinical, Lab, Consulting), Therapeutic Area (Oncology, Infectious Disease, Neurology, Immunology, Hematology, Vaccines, Cell & Gene Therapy), End User & Region - Global Forecast to 2028

Report Code: PH 4672 Feb, 2023, by marketsandmarkets.com

The global CRO services market in terms of revenue was estimated to be worth $76.6 billion in 2023 and is poised to reach $127.3 billion by 2028, growing at a CAGR of 10.7% from 2023 to 2028.

Factors such as continuously growing pharmaceutical, biopharmaceutical, and medical device R&D pipelines and technological advancements in the clinical trials process are driving the growth of this market. Besides, the growing demand for new clinical trial designs for cell & gene therapies is expected to offer growth opportunities to companies operating in this market.

Attractive Opportunities in the Contract Research Organization (CRO) Services Market

Contract Research Organization (CRO) Services Market

To know about the assumptions considered for the study, Request for Free Sample Report

CRO Services Market Dynamics

DRIVERS: Growing size of the drug R&D pipeline

Over the last decade, the drug discovery and development field has grown consistently. There has been continuous growth in the number of clinical studies conducted, resulting in novel drug molecules entering various phases of the clinical drug development cycle. According to Pharma R&D Annual Review 2022, the number of drugs in the R&D pipeline grew from 17,737 in 2020 to 20,109 in 2022. As per the ClinicalTrials.gov website, the number of registered studies went up from 32,517 in 2019 to 36,770 in 2022, at a CAGR of 4.2% between 2019 and 2022. This growth in the R&D pipeline of novel drugs is boosting the outsourcing of the drug development process with an aim to manage capacities and access scientific and process innovations to develop cost-effective and efficient drug molecules ultimately. This is expected to drive the CRO Services market growth.

OPPORTUNITIES: Need for novel clinical trial designs for complex cell & gene therapies

Cell & gene therapies are complex and very specific. They are perceived to address unmet medical needs. This has led to increased investment in developing and commercializing new cell & gene therapies. As of April 2021, 16 cell & gene therapies have been approved by the US FDA. In 2020, around 362 cell & gene therapies were under clinical development. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development, has increased the demand for facilities that offer R&D services for these therapies. Thus, the end users, like Biotech companies and academia, prefer reliance on CROs for their specialized skills and scientific expertise. Besides, CROs also offer greater regulatory clarity and global reach for clinical studies. These factors are, thus, expected to drive the CRO services market.

CHALLENGES: Patient recruitment and retention for clinical studies

One of the major and unaddressed challenges for CROs, CDMOs, and life science companies is Patient recruitment and retention. The main challenges related to patient recruitment include protocol complexities and competition in clinical trials, which makes it increasingly hard to find qualified patients. Moreover, a lack of understanding of the patient's perspective is another factor that makes it difficult for recruiters to retain patients throughout the trial. However, decentralized clinical trial services are likely to reduce the effects of this challenge over the coming years. Many of the service providers of patient recruitment rely heavily on offline recruitment through marketing in newspapers, public transport, or street posters. In contrast, organizers rely heavily on doctors and study center recruitment. This can be overcome through the use of social media and various other online marketing channels.

The Clinical Research Services subsegment of the type segment dominated the Contract Research Organization (CRO) Services Market in 2022:

Based on type, the CRO services market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services. The clinical research services segment accounted for the largest share of this market in 2022. The large share of this segment can primarily be attributed to factors such as the growing size of the R&D pipeline of drugs and high clinical trial expenses.

Contract Research Organization (CRO) Services Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for Contract Research Organization (CRO) Services Market in 2022.

North America accounted for the largest share of the global Contract Research Organization (CRO) Services market. As a result of the growing outsourcing of R&D activities to CRO and the increasing number of clinical studies being conducted in the region, North America holds the largest share.

The key players in the global Contract Research Organization (CRO) Services market are IQVIA (US), Laboratory Corporation of America Holdings (US), PPD (US), ICON (US), WuXi AppTec (China), Syneos Health (US), Charles River Laboratories International (US), and Medpace Holdings (US).

CRO Services Market Scope

Report Metric

Details

Market size available for years

2023-2028

Base year considered

2022

Forecast period

2023-2028

Forecast units

Value (USD)

Segments covered

Type, Therapeutic area, End user and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA)

Companies covered

IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), PPD, Inc. (a part of Thermo Fisher Scientific, Inc.) (US), Syneos Health Inc. (US), WuXi AppTec Co., Ltd. (China), Charles River Laboratories International, Inc. (US), Parexel International Corporation (US), Pharmaron Beijing Co., Ltd. (China), ICON Plc (Ireland), Medpace Holdings Inc. (US), SGS SA (Switzerland), Frontage Holdings Corporation (US), PSI CRO AG (Switzerland), BioAgile Therapeutics Pvt. Ltd. (India), Firma Clinical Research, LLC (US), AccuLab Life Sciences (US), Novotech Health Holdings (Australia), KCR S.A. (US), Linical Co., Ltd. (Japan), Advanced Clinical (US), Azelix LLC (US), Clinical Trial Service BV (Netherlands), Pepgra Healthcare Pvt. Ltd. (UK), Worldwide Clinical Trials Holdings Inc. (US), and CTI Clinical Trial and Consulting Services Inc. (US)

This report categorizes the CRO services market into the following segments and subsegments:

By Type

  • Clinical Research Services
  • Early phase development Services
  • Laboratory Services
  • Consulting Services
  • Data Managenment Services

By Clinical Research Services

  • Phase III
  • Phase II
  • Phase I
  • Phase IV

By Early Phase Development Services

  • Chemistry, Manufacturing and Controls Services
  • Preclinical Services
  • Pharmacokinetics/ Pharmacodynamics Services
  • Toxicology Testing Services
  • Other Preclinical Services
  • Discovery Studies

By Laboratory Services

  • Analytical Testing Services
    • Physical Characterization Services
    • Raw Material Testing Services
    • Batch Release Testing Services
    • Stability Testing Services
    • Other Analytical Testing Services
  • Bioanalytical Testing Services

By Therapeutic Area

  • Oncology
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Other Cancer
  • Infectious Diseases
  • CVS Disorders
  • Neurology
  • Vaccines
  • Metabolic Disorders/Endocrinology
  • Immunological Disorders
  • Psychiatry
  • Respiratory Disorders
  • Dermatology
  • Ophthalmology
  • Gastrointestinal Diseases
  • Genitourinary & Women’s Health
  • Hematology
  • Other Therapeutic Areas

By End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Academic Institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
    • Brazil
    • RoLATAM
  • Middle East and Africa (MEA)

Recent Developments

  • In November 2022, IQVIA (US) collaborated with Clalit Health Services (Israel) to combine their clinical trial delivery, real-world research, data, and genomics capabilities.
  • In October 2022, the PPD clinical research business of Thermo Fisher Scientific launched the Decentralized Clinical Trials Network to support global investigators and research sites participating in decentralized clinical trials (DCTs).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 58)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
          FIGURE 1 CRO SERVICES MARKET SEGMENTATION
           1.3.1 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 64)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022
          FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
          FIGURE 6 ILLUSTRATIVE EXAMPLE OF IQVIA: REVENUE SHARE ANALYSIS, 2022
           2.2.1 INSIGHTS FROM PRIMARIES
                    FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
                    FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH FORECAST 
          FIGURE 9 GLOBAL MARKET: CAGR PROJECTIONS, 2023–2028
          FIGURE 10 GLOBAL MARKET: GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ON GLOBAL MARKET 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 77)
    FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 GLOBAL MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 GLOBAL MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT: GLOBAL MARKET
 
4 PREMIUM INSIGHTS (Page No. - 81)
    4.1 CRO SERVICES MARKET OVERVIEW 
          FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: MARKET SHARE,  BY TYPE & COUNTRY (2022) 
          FIGURE 17 CLINICAL RESEARCH SERVICES DOMINATED NORTH AMERICAN MARKET IN 2022
    4.3 GLOBAL MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 
          FIGURE 18 CLINICAL RESEARCH SERVICES TO CONTINUE TO DOMINATE MARKET BY 2028
    4.4 GLOBAL MARKET SHARE, BY END USER, 2022 
          FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.5 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          221`FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN GLOBAL MARKET FROM 2023 TO 2028
 
5 MARKET OVERVIEW (Page No. - 85)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 CRO SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 GLOBAL MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing drug R&D pipeline
                                FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2012–2022
                                FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028
                    5.2.1.2 Technological advancements in clinical trials
                    5.2.1.3 High cost of in-house drug development
                                FIGURE 24 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUNDS FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Need for novel clinical trial designs for complex cell & gene therapies
                    5.2.2.2 Emergence of hybrid models with CRO-CDMO partnerships
           5.2.3 CHALLENGES
                    5.2.3.1 Patient recruitment and retention for clinical trials
                    5.2.3.2 Shortage of skilled professionals for clinical trials
    5.3 MARKET TRENDS 
           5.3.1 INDUSTRY CONSOLIDATION
                    TABLE 5 LIST OF ACQUISITIONS
           5.3.2 DECENTRALIZED CLINICAL TRIALS
           5.3.3 REAL-WORLD DATA (RWD) AND REAL-WORLD EVIDENCE (RWE)
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 25 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS
    5.5 PRICING ANALYSIS 
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 26 VALUE CHAIN ANALYSIS OF GLOBAL MARKET: CLINICAL RESEARCH PHASE ADDS MAXIMUM VALUE
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 27 ECOSYSTEM ANALYSIS: GLOBAL MARKET
          TABLE 6 OVERALL MARKET ECOSYSTEM FOR CRO SERVICES
    5.8 TECHNOLOGY ANALYSIS 
    5.9 CASE STUDY ANALYSIS 
           5.9.1 USING LAB DATA INSIGHTS TO IMPROVE POPULATION MANAGEMENT OF CHRONIC KIDNEY DISEASE (CKD)
           5.9.2 IQVIA FOCUSES ON LEVERAGING AI AND ML TO IMPROVE SERVICE OFFERINGS
    5.10 KEY CONFERENCES & EVENTS IN 2022–2023 
           TABLE 7 GLOBAL MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.11 REGULATORY ANALYSIS 
           5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 11 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 12 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT FROM NEW ENTRANTS
           5.12.2 THREAT FROM SUBSTITUTES
           5.12.3 BARGAINING POWER OF BUYERS
           5.12.4 BARGAINING POWER OF SUPPLIERS
           5.12.5 DEGREE OF COMPETITION
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES
           5.13.2 BUYING CRITERIA FOR CRO SERVICES
                     FIGURE 29 KEY BUYING CRITERIA FOR END USERS
 
6 CRO SERVICES MARKET, BY TYPE (Page No. - 110)
    6.1 INTRODUCTION 
          TABLE 13 GLOBAL MARKET, BY TYPE, 2021–2028 (USD MILLION)
    6.2 CLINICAL RESEARCH SERVICES 
          TABLE 14 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF DECEMBER 2022,  BY LOCATION
          TABLE 15 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
          FIGURE 30 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021 VS. 2022
          TABLE 16 CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
          TABLE 17 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 18 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 19 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 20 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 21 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           6.2.1 PHASE III CLINICAL RESEARCH SERVICES
                    6.2.1.1 High cost of Phase III trials to drive demand for cost-effective CRO services
                                TABLE 22 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDIES
                                TABLE 23 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 24 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 25 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 26 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 27 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           6.2.2 PHASE II CLINICAL RESEARCH SERVICES
                    6.2.2.1 Growing significance of Phase II studies to provide growth opportunities for CROs
                                TABLE 28 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
                                TABLE 29 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 30 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 31 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 32 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 33 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           6.2.3 PHASE I CLINICAL RESEARCH SERVICES
                    6.2.3.1 Growing R&D pipeline of pharmaceutical companies to support growth
                                TABLE 34 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES
                                TABLE 35 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 36 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 37 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 38 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 39 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           6.2.4 PHASE IV CLINICAL RESEARCH SERVICES
                    6.2.4.1 Increasing number of CROs providing post-marketing surveillance to boost market
                                TABLE 40 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
                                TABLE 41 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 42 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 43 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 44 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 45 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    6.3 EARLY-PHASE DEVELOPMENT SERVICES 
          FIGURE 31 DRUGS IN DEVELOPMENT, BY THERAPEUTIC AREA (2022)
          TABLE 46 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS
          TABLE 47 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 48 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
          TABLE 49 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 50 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 51 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 52 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           6.3.1 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES
                    6.3.1.1 Growing need to meet regulatory standards for drugs to drive demand for CMC services
                                TABLE 53 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 54 NORTH AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 55 EUROPE: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 56 ASIA PACIFIC: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 57 LATIN AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.2 PRECLINICAL SERVICES
                    TABLE 58 PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 59 PRECLINICAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 60 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 61 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 62 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 63 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    6.3.2.1 Pharmacokinetics/Pharmacodynamics services
                               6.3.2.1.1 Importance of understanding interactions between body and administered drugs to drive uptake of PK/PD studies
                                              TABLE 64 PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
                                              TABLE 65 NORTH AMERICA: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 66 EUROPE: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 67 ASIA PACIFIC: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 68 LATIN AMERICA: PHARMACOKINETICS/PHARMACOKINETICS SERVICES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.2.2 Toxicology testing services
                               6.3.2.2.1 Need to prevent late-stage failures to boost demand for toxicology testing
                                              TABLE 69 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 70 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 71 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 72 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 73 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    6.3.2.3 Other preclinical services
                                TABLE 74 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 75 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 76 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 77 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 78 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           6.3.3 DISCOVERY STUDIES
                    6.3.3.1 Increasing reliance on CRO services for target identification and validation to promote growth
                                TABLE 79 DISCOVERY STUDIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 80 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 81 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 82 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 83 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 LABORATORY SERVICES 
          TABLE 84 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
          TABLE 85 LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 86 LABORATORY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 87 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 88 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 89 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 90 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           6.4.1 ANALYTICAL TESTING SERVICES
                    TABLE 91 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 92 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 93 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 94 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 95 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 96 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    6.4.1.1 Physical characterization services
                               6.4.1.1.1 Growing need to reduce risk of product failure to drive demand for physical characterization services
                                              TABLE 97 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION,  2021–2028 (USD MILLION)
                                              TABLE 98 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET,  BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 99 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 100 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 101 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    6.4.1.2 Raw material testing services
                               6.4.1.2.1 Need to ensure quality and purity of raw materials to support demand for raw material testing services
                                              TABLE 102 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 103 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 104 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 105 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 106 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    6.4.1.3 Batch-release testing services
                               6.4.1.3.1 Comprehensive portfolio of batch-release testing services offered by CROs to propel growth
                                              TABLE 107 BATCH-RELEASE TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 108 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 109 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 110 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 111 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    6.4.1.4 Stability testing services
                               6.4.1.4.1 Need to ensure long-term quality, safety, and efficacy of pharmaceutical products to boost uptake of stability testing
                                              TABLE 112 STABILITY TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 113 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 114 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 115 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                              TABLE 116 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    6.4.1.5 Other analytical testing services
                                TABLE 117 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 118 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 119 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 120 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 121 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           6.4.2 BIOANALYTICAL TESTING SERVICES
                    6.4.2.1 Importance of accurate PK/PD studies to drive demand for bioanalytical testing services
                                TABLE 122 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 123 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 124 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 125 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 126 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    6.5 CONSULTING SERVICES 
           6.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER AND MORE STREAMLINED REGULATORY APPROVALS TO BOOST MARKET
                    TABLE 127 EXAMPLES OF CONSULTING SERVICES OFFERED BY PROMINENT PLAYERS
                    TABLE 128 CONSULTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 129 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 130 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 131 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 132 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
    6.6 DATA MANAGEMENT SERVICES 
           6.6.1 DATA MANAGEMENT SERVICES TO RECORD HIGHEST CAGR DURING FORECAST PERIOD
                    TABLE 133 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
                    TABLE 134 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 135 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 136 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 137 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 138 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
 
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 177)
    7.1 INTRODUCTION 
          TABLE 139 GLOBAL MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
    7.2 ONCOLOGY 
          FIGURE 32 NUMBER OF ONCOLOGY CLINICAL TRIALS, 2012–2022 (THOUSAND)
          TABLE 140 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2022)
          TABLE 141 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
          TABLE 142 GLOBAL MARKET FOR ONCOLOGY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 143 GLOBAL MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
          TABLE 144 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 145 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 146 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 147 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
           7.2.1 BREAST CANCER
                    7.2.1.1 High prevalence of breast cancer to drive market growth
                                TABLE 148 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 149 NORTH AMERICA: MARKET FOR BREAST CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 150 EUROPE: MARKET FOR BREAST CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 151 ASIA PACIFIC: MARKET FOR BREAST CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 152 LATIN AMERICA: MARKET FOR BREAST CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
           7.2.2 LUNG CANCER
                    7.2.2.1 Increasing drug approvals to boost research on lung cancer
                                TABLE 153 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 154 NORTH AMERICA: MARKET FOR LUNG CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 155 EUROPE: MARKET FOR LUNG CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 156 ASIA PACIFIC: MARKET FOR LUNG CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 157 LATIN AMERICA: MARKET FOR LUNG CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
           7.2.3 COLORECTAL CANCER
                    7.2.3.1 Increasing incidence of colorectal cancer to drive drug research activities worldwide
                                TABLE 158 GLOBAL MARKET FOR COLORECTAL CANCER, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 159 NORTH AMERICA: MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 160 EUROPE: MARKET FOR COLORECTAL CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 161 ASIA PACIFIC: MARKET FOR COLORECTAL CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 162 LATIN AMERICA: MARKET FOR COLORECTAL CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
           7.2.4 PROSTATE CANCER
                    7.2.4.1 Increasing research initiatives on prostate cancer to drive growth
                                TABLE 163 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 164 NORTH AMERICA: MARKET FOR PROSTATE CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 165 EUROPE: MARKET FOR PROSTATE CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 166 ASIA PACIFIC: MARKET FOR PROSTATE CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 167 LATIN AMERICA: MARKET FOR PROSTATE CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
           7.2.5 OTHER CANCERS
                    TABLE 168 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 169 NORTH AMERICA: MARKET FOR OTHER CANCERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 170 EUROPE: MARKET FOR OTHER CANCERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 171 ASIA PACIFIC: MARKET FOR OTHER CANCERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 172 LATIN AMERICA: MARKET FOR OTHER CANCERS, BY COUNTRY,  2021–2028 (USD MILLION)
    7.3 INFECTIOUS DISEASES 
           7.3.1 INCREASING EPIDEMIC OUTBREAKS TO DRIVE DRUG DISCOVERY ACTIVITIES
                    TABLE 173 GLOBAL MARKET FOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 174 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 175 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 176 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 177 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
    7.4 CARDIOVASCULAR SYSTEM DISORDERS 
           7.4.1 HIGH MORTALITY RATES TO COMPEL PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
                    TABLE 178 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (AS OF DECEMBER 2022)
                    TABLE 179 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 180 NORTH AMERICA: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 181 EUROPE: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 182 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 183 LATIN AMERICA: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 NEUROLOGY 
           7.5.1 INCREASING INVESTMENTS IN R&D FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET
                    TABLE 184 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2022)
                    TABLE 185 GLOBAL MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 186 NORTH AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 187 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 188 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 189 LATIN AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    7.6 VACCINES 
           7.6.1 NORMALIZATION OF VACCINES MARKET GROWTH TO PRE-COVID TIMES TO RESTRAIN MARKET GROWTH
                    TABLE 190 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 191 NORTH AMERICA: MARKET FOR VACCINES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 192 EUROPE: MARKET FOR VACCINES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 193 ASIA PACIFIC: MARKET FOR VACCINES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 194 LATIN AMERICA: MARKET FOR VACCINES, BY COUNTRY,  2021–2028 (USD MILLION)
    7.7 METABOLIC DISORDERS/ENDOCRINOLOGY 
           7.7.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET
                    FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES,  2000–2045 (MILLION)
                    TABLE 195 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 196 NORTH AMERICA: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 197 EUROPE: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 198 ASIA PACIFIC: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 199 LATIN AMERICA: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.8 IMMUNOLOGICAL DISORDERS 
           7.8.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
                    TABLE 200 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)
                    TABLE 201 GLOBAL MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 202 NORTH AMERICA: MARKET FOR IMMUNOLOGICAL DISORDERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 203 EUROPE: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 204 ASIA PACIFIC: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 205 LATIN AMERICA: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.9 PSYCHIATRY 
           7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL GROWTH
                    TABLE 206 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 207 NORTH AMERICA: MARKET FOR PSYCHIATRY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 208 EUROPE: MARKET FOR PSYCHIATRY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 209 ASIA PACIFIC: MARKET FOR PSYCHIATRY, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 210 LATIN AMERICA: MARKET FOR PSYCHIATRY, BY COUNTRY,  2021–2028 (USD MILLION)
    7.10 RESPIRATORY DISORDERS 
           7.10.1 GROWING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
                     TABLE 211 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2022)
                     TABLE 212 GLOBAL MARKET FOR RESPIRATORY DISORDERS, BY REGION,  2021–2028 (USD MILLION)
                     TABLE 213 NORTH AMERICA: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                     TABLE 214 EUROPE: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 215 ASIA PACIFIC: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
                     TABLE 216 LATIN AMERICA: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.11 DERMATOLOGY 
           7.11.1 GROWING DRUG DEVELOPMENT FOR VARIOUS SKIN DISORDERS TO PROPEL MARKET
                     TABLE 217 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022)
                     TABLE 218 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2021–2028 (USD MILLION)
                     TABLE 219 NORTH AMERICA: MARKET FOR DERMATOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 220 EUROPE: MARKET FOR DERMATOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 221 ASIA PACIFIC: MARKET FOR DERMATOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 222 LATIN AMERICA: MARKET FOR DERMATOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    7.12 OPHTHALMOLOGY 
           7.12.1 GROWING OPHTHALMOLOGY-RELATED CLINICAL TRIALS TO DRIVE SEGMENT
                     TABLE 223 GLOBAL MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)
                     TABLE 224 NORTH AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 225 EUROPE: MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 226 ASIA PACIFIC: MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 227 LATIN AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    7.13 GASTROINTESTINAL DISEASES 
           7.13.1 GROWING R&D PIPELINE FOR GASTROINTESTINAL DISEASES  TO AID GROWTH
                     TABLE 228 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION,  2021–2028 (USD MILLION)
                     TABLE 229 NORTH AMERICA: MARKET FOR GASTROINTESTINAL DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                     TABLE 230 EUROPE: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 231 ASIA PACIFIC: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                     TABLE 232 LATIN AMERICA: MARKET FOR GASTROINTESTINAL DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
    7.14 GENITOURINARY & WOMEN’S HEALTH 
           7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET
                     TABLE 233 GLOBAL MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY REGION,  2021–2028 (USD MILLION)
                     TABLE 234 NORTH AMERICA: MARKET FOR GENITOURINARY AND WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION)
                     TABLE 235 EUROPE: MARKET FOR GENITOURINARY AND WOMEN’S HEALTH,  BY COUNTRY, 2021–2028 (USD MILLION)
                     TABLE 236 ASIA PACIFIC: MARKET FOR GENITOURINARY AND WOMEN’S HEALTH,  BY COUNTRY, 2021–2028 (USD MILLION)
                     TABLE 237 LATIN AMERICA: MARKET FOR GENITOURINARY AND WOMEN’S HEALTH,  BY COUNTRY, 2021–2028 (USD MILLION)
    7.15 HEMATOLOGY 
           7.15.1 DEVELOPMENT OF DRUGS FOR HEMATOLOGICAL DISORDERS TO DRIVE GROWTH
                     TABLE 238 CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2021–2028 (USD MILLION)
                     TABLE 239 NORTH AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 240 EUROPE: MARKET FOR HEMATOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 241 ASIA PACIFIC: MARKET FOR HEMATOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
                     TABLE 242 LATIN AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY,  2021–2028 (USD MILLION)
    7.16 OTHER THERAPEUTIC AREAS 
            TABLE 243 GLOBAL MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION,  2021–2028 (USD MILLION)
            TABLE 244 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
            TABLE 245 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY,  2021–2028 (USD MILLION)
            TABLE 246 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
            TABLE 247 LATIN AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.17 CUSTOMIZATION 
           7.17.1 CELL & GENE THERAPY
                    7.17.1.1 Favorable funding scenario for R&D to support growth
                                TABLE 248 CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 249 NORTH AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 250 EUROPE: MARKET FOR CELL & GENE THERAPY, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 251 ASIA PACIFIC: MARKET FOR CELL & GENE THERAPY, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 252 LATIN AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY,  2021–2028 (USD MILLION)
           7.17.2 RARE DISEASES
                    7.17.2.1 Growth in drug R&D pipeline for rare diseases to drive market
                                TABLE 253 GLOBAL MARKET FOR RARE DISEASES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 254 NORTH AMERICA: MARKET FOR RARE DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 255 EUROPE: MARKET FOR RARE DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 256 ASIA PACIFIC: MARKET FOR RARE DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 257 LATIN AMERICA: MARKET FOR RARE DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
           7.17.3 BIOSIMILARS
                    7.17.3.1 Patent expiration of biologics to boost market
                                TABLE 258 CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 259 NORTH AMERICA: MARKET FOR BIOSIMILARS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 260 EUROPE: MARKET FOR BIOSIMILARS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 261 ASIA PACIFIC: MARKET FOR BIOSIMILARS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 262 LATIN AMERICA: MARKET FOR BIOSIMILARS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 263 GLOBAL MARKET FOR BIOSIMILARS, BY TYPE, 2021–2028 (USD MILLION)
                    7.17.3.2 Monoclonal antibodies
                                TABLE 264 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 265 NORTH AMERICA: MARKET FOR MONOCLONAL ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 266 EUROPE: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 267 ASIA PACIFIC: MARKET FOR MONOCLONAL ANTIBODIES BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 268 LATIN AMERICA: MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.17.3.3 Insulin
                                TABLE 269 CRO SERVICES MARKET FOR INSULIN, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 270 NORTH AMERICA: MARKET FOR INSULIN, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 271 EUROPE: MARKET FOR INSULIN, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 272 ASIA PACIFIC: MARKET FOR INSULIN, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 273 LATIN AMERICA: MARKET FOR INSULIN, BY COUNTRY,  2021–2028 (USD MILLION)
                    7.17.3.4 CSF
                                TABLE 274 GLOBAL MARKET FOR CSF, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 275 NORTH AMERICA: MARKET FOR CSF, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 276 EUROPE: MARKET FOR CSF, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 277 ASIA PACIFIC: MARKET FOR CSF, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 278 LATIN AMERICA: MARKET FOR CSF, BY COUNTRY,  2021–2028 (USD MILLION)
                    7.17.3.5 Erythropoietin
                                TABLE 279 CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 280 NORTH AMERICA: MARKET FOR ERYTHROPOIETIN, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 281 EUROPE: MARKET FOR ERYTHROPOIETIN, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 282 ASIA PACIFIC: MARKET FOR ERYTHROPOIETIN, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 283 LATIN AMERICA: MARKET FOR ERYTHROPOIETIN, BY COUNTRY,  2021–2028 (USD MILLION)
                    7.17.3.6 Other biosimilars
                                TABLE 284 GLOBAL MARKET FOR OTHER BIOSIMILARS, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 285 NORTH AMERICA: MARKET FOR OTHER BIOSIMILARS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 286 EUROPE: MARKET FOR OTHER BIOSIMILARS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 287 ASIA PACIFIC: MARKET FOR OTHER BIOSIMILARS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 288 LATIN AMERICA: MARKET FOR OTHER BIOSIMILARS, BY COUNTRY,  2021–2028 (USD MILLION)
 
8 CRO SERVICES MARKET, BY END USER (Page No. - 256)
    8.1 INTRODUCTION 
          TABLE 289 GLOBAL MARKET, BY END USER, 2021–2028 (USD MILLION)
    8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 
           8.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINES TO DRIVE MARKET GROWTH
                    FIGURE 34 ANNUAL DRUG APPROVALS BY CDER (FDA), 2012–2021
                    FIGURE 35 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2012–2021
                    TABLE 290 GLOBAL MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 291 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 292 EUROPE: MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 293 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 294 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 MEDICAL DEVICE COMPANIES 
           8.3.1 INCREASING R&D FOR DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO SUPPORT GROWTH
                    FIGURE 36 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2012–2022)
                    TABLE 295 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 296 NORTH AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 297 EUROPE: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 298 ASIA PACIFIC: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 299 LATIN AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES,  BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 ACADEMIC INSTITUTES 
           8.4.1 INCREASING COLLABORATIONS BETWEEN CROS AND ACADEMIC INSTITUTES TO BOOST MARKET
                    TABLE 300 GLOBAL MARKET FOR ACADEMIC INSTITUTES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 301 NORTH AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 302 EUROPE: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 303 ASIA PACIFIC: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 304 LATIN AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 CRO SERVICES MARKET, BY REGION (Page No. - 269)
    9.1 INTRODUCTION 
          TABLE 305 GLOBAL MARKET, BY REGION, 2021–2028 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 37 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT
          TABLE 306 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 307 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 308 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
          TABLE 309 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 310 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 311 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 312 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 313 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
          TABLE 314 NORTH AMERICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 315 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US to dominate CRO services market in North America
                                FIGURE 38 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)
                                TABLE 316 US: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 317 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                TABLE 318 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 319 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 320 US: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 321 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 322 US: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 323 US: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 324 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Favorable regulations to support market growth
                                TABLE 325 CANADA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 326 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
                                TABLE 327 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 328 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 329 CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 330 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 331 CANADA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 332 CANADA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 333 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.3 NORTH AMERICA: RECESSION IMPACT
    9.3 EUROPE 
          TABLE 334 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 335 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 336 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
          TABLE 337 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 338 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 339 EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 340 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 341 EUROPE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
          TABLE 342 EUROPE: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 343 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Growing outsourcing and government support to propel market
                                TABLE 344 GERMANY: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 345 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
                                TABLE 346 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 347 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 348 GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 349 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 350 GERMANY: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 351 GERMANY: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 352 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Investments by pharmaceutical sponsors for drug discovery services to boost market
                                FIGURE 39 UK: PHARMACEUTICAL R&D EXPENDITURE, 2011–2020 (USD MILLION)
                                TABLE 353 UK: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 354 UK: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                TABLE 355 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 356 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 357 UK: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 358 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 359 UK: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 360 UK: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 361 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Favorable drug research environment to drive market growth
                                TABLE 362 FRANCE: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 363 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
                                TABLE 364 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 365 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 366 FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 367 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 368 FRANCE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 369 FRANCE: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 370 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Low drug approval time and growing research funding to fuel growth
                                TABLE 371 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022)
                                TABLE 372 ITALY: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 373 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                TABLE 374 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 375 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 376 ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 377 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 378 ITALY: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 379 ITALY: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 380 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Rising R&D expenditure to boost market
                                TABLE 381 SPAIN: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 382 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                TABLE 383 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 384 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 385 SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 386 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 387 SPAIN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 388 SPAIN: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 389 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 390 REST OF EUROPE: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 391 REST OF EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
                    TABLE 392 REST OF EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 393 REST OF EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 394 REST OF EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 395 REST OF EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 396 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                    TABLE 397 REST OF EUROPE: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 398 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.7 EUROPE: RECESSION IMPACT
    9.4 ASIA PACIFIC 
          FIGURE 40 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT
          TABLE 399 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 400 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 401 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
          TABLE 402 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 403 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 404 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 405 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 406 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
          TABLE 407 ASIA PACIFIC: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 408 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 China to dominate APAC CRO services market
                                TABLE 409 CHINA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 410 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                TABLE 411 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 412 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 413 CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 414 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 415 CHINA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 416 CHINA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 417 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Strong focus on research to drive market growth
                                TABLE 418 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2020 VS. 2022
                                TABLE 419 JAPAN: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 420 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                TABLE 421 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 422 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 423 JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 424 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 425 JAPAN: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 426 JAPAN: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 427 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Growing pharmaceutical industry to create favorable opportunities for market players
                                TABLE 428 INDIA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 429 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                TABLE 430 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 431 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 432 INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 433 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 434 INDIA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 435 INDIA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 436 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 Large number of research institutes to make Australia a favorable location for drug discovery
                                TABLE 437 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 438 AUSTRALIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
                                TABLE 439 AUSTRALIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 440 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 441 AUSTRALIA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 442 AUSTRALIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 443 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 444 AUSTRALIA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 445 AUSTRALIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.5 SOUTH KOREA
                    9.4.5.1 Government initiatives and growing R&D activities for drug development to drive growth
                                TABLE 446 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 447 SOUTH KOREA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
                                TABLE 448 SOUTH KOREA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 449 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 450 SOUTH KOREA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 451 SOUTH KOREA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 452 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                                TABLE 453 SOUTH KOREA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 454 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.6 REST OF ASIA PACIFIC (ROAPAC)
                    TABLE 455 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 456 REST OF ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
                    TABLE 457 REST OF ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 458 REST OF ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 459 REST OF ASIA PACIFIC: LABORATORY SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 460 REST OF ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 461 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                    TABLE 462 REST OF ASIA PACIFIC: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 463 REST OF ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.4.7 ASIA PACIFIC: RECESSION IMPACT
    9.5 LATIN AMERICA 
          TABLE 464 LATIN AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 465 LATIN AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 466 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
          TABLE 467 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 468 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 469 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 470 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 471 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
          TABLE 472 LATIN AMERICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 473 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.5.1 BRAZIL
                    9.5.1.1 Gradual growth in research to contribute to growth
                                TABLE 474 BRAZIL: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 475 BRAZIL: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2021–2028 (USD MILLION)
                                TABLE 476 BRAZIL: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 477 BRAZIL: PRECLINICAL SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 478 BRAZIL: LABORATORY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 479 BRAZIL: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 480 BRAZIL: MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
                                TABLE 481 BRAZIL: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 482 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.5.2 REST OF LATIN AMERICA
                    TABLE 483 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 484 REST OF LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
                    TABLE 485 REST OF LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 486 REST OF LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 487 REST OF LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 488 REST OF LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 489 REST OF LATIN AMERICA: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                    TABLE 490 REST OF LATIN AMERICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 491 REST OF LATIN AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.5.3 LATIN AMERICA: RECESSION IMPACT
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
                    TABLE 492 MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 493 MIDDLE EAST & AFRICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE,  2021–2028 (USD MILLION)
                    TABLE 494 MIDDLE EAST & AFRICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 495 MIDDLE EAST & AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 496 MIDDLE EAST & AFRICA: LABORATORY SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 497 MIDDLE EAST & AFRICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 498 MIDDLE EAST & AFRICA: MARKET, BY THERAPEUTIC AREA,  2021–2028 (USD MILLION)
                    TABLE 499 MIDDLE EAST & AFRICA: ONCOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 500 MIDDLE EAST & AFRICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
10 COMPETITIVE LANDSCAPE (Page No. - 365)
     10.1 INTRODUCTION 
     10.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 41 CRO SERVICES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     10.3 REVENUE SHARE ANALYSIS 
             FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
     10.4 MARKET SHARE ANALYSIS 
             FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
             TABLE 501 GLOBAL MARKET: DEGREE OF COMPETITION
     10.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS 
             FIGURE 44 GLOBAL MARKET: COMPANY EVALUATION MATRIX  FOR KEY PLAYERS, 2022
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
     10.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 
             10.6.1 INDUSTRY FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 502 INDUSTRY FOOTPRINT ANALYSIS OF KEY PLAYERS IN GLOBAL MARKET
             10.6.2 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 503 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN GLOBAL MARKET
             10.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
                        TABLE 504 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN SERVICES MARKET
     10.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES 
             FIGURE 45 GLOBAL MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
             10.7.1 PROGRESSIVE COMPANIES
             10.7.2 STARTING BLOCKS
             10.7.3 RESPONSIVE COMPANIES
             10.7.4 DYNAMIC COMPANIES
     10.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 
             TABLE 505 GLOBAL MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
             TABLE 506 GLOBAL MARKET: COMPETITIVE BENCHMARKING OF START-UP/SMES
     10.9 COMPETITIVE SCENARIOS AND TRENDS 
             10.9.1 SERVICE LAUNCHES
                        TABLE 507 GLOBAL MARKET: SERVICE LAUNCHES, JANUARY 2020–DECEMBER 2022
             10.9.2 DEALS
                        TABLE 508 GLOBAL MARKET: DEALS, JANUARY 2020–DECEMBER 2022
             10.9.3 OTHER DEVELOPMENTS
                        TABLE 509 CRO SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2020–DECEMBER 2022
 
11 COMPANY PROFILES (Page No. - 381)
     11.1 KEY COMPANIES 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             11.1.1 IQVIA
                        TABLE 510 IQVIA: BUSINESS OVERVIEW
                        FIGURE 46 IQVIA: COMPANY SNAPSHOT (2021)
             11.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)
                        TABLE 511 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
                        FIGURE 47 LABORATORY CORPORATION OF AMERICA HOLDINGS:  COMPANY SNAPSHOT (2021)
             11.1.3 PPD INC. (A PART OF THERMO FISHER SCIENTIFIC, INC.)
                        TABLE 512 PPD INC.: BUSINESS OVERVIEW
                        FIGURE 48 PPD INC.: COMPANY SNAPSHOT (2021)
             11.1.4 SYNEOS HEALTH INC.
                        TABLE 513 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
                        FIGURE 49 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021)
             11.1.5 WUXI APPTEC CO., LTD.
                        TABLE 514 WUXI APPTEC CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 50 WUXI APPTEC CO., LTD.: COMPANY SNAPSHOT (2021)
             11.1.6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                        TABLE 515 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
                        FIGURE 51 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.:  COMPANY SNAPSHOT (2021)
             11.1.7 PAREXEL INTERNATIONAL CORPORATION
                        TABLE 516 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
             11.1.8 PHARMARON BEIJING CO., LTD.
                        TABLE 517 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 52 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2021)
             11.1.9 ICON PLC
                        TABLE 518 ICON PLC: BUSINESS OVERVIEW
                        FIGURE 53 ICON PLC: COMPANY SNAPSHOT (2021)
             11.1.10 MEDPACE HOLDINGS, INC.
                        TABLE 519 MEDPACE HOLDINGS, INC.: BUSINESS OVERVIEW
                        FIGURE 54 MEDPACE HOLDINGS, INC.: COMPANY SNAPSHOT (2021)
             11.1.11 SGS SA
                        TABLE 520 SGS SA: BUSINESS OVERVIEW
                        FIGURE 55 SGS SA: COMPANY SNAPSHOT (2021)
             11.1.12 FRONTAGE HOLDINGS CORPORATION
                        TABLE 521 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 56 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
             11.1.13 PSI CRO AG
                        TABLE 522 PSI CRO AG: BUSINESS OVERVIEW
             11.1.14 BIOAGILE THERAPEUTICS PVT. LTD.
                        TABLE 523 BIOAGILE THERAPEUTICS PVT. LTD.: BUSINESS OVERVIEW
             11.1.15 FIRMA CLINICAL RESEARCH, LLC
                        TABLE 524 FIRMA CLINICAL RESEARCH, LLC: BUSINESS OVERVIEW
             11.1.16 ACCULAB LIFE SCIENCES
                        TABLE 525 ACCULAB LIFE SCIENCES: BUSINESS OVERVIEW
             11.1.17 NOVOTECH HEALTH HOLDINGS
                        TABLE 526 NOVOTECH HEALTH HOLDINGS: BUSINESS OVERVIEW
             11.1.18 KCR (FORMERLY KIECANA CLINICAL RESEARCH)
                        TABLE 527 KCR: BUSINESS OVERVIEW
             11.1.19 LINICAL CO., LTD.
                        TABLE 528 LINICAL CO., LTD.: BUSINESS OVERVIEW
             11.1.20 ADVANCED CLINICAL
                        TABLE 529 ADVANCED CLINICAL: BUSINESS OVERVIEW
     11.2 OTHER PLAYERS 
             11.2.1 AZELIX LLC
             11.2.2 CLINICAL TRIAL SERVICE BV
             11.2.3 PEPGRA HEALTHCARE PVT. LTD.
             11.2.4 WORLDWIDE CLINICAL TRIALS HOLDINGS INC.
             11.2.5 CTI CLINICAL TRIAL AND CONSULTING SERVICES, INC.
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
12 APPENDIX (Page No. - 467)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global Contract Research Organization (CROs) Services Market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the Association of Clinical Research Organizations (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICRO), Clinical and Contract Research Association (CCRA), ClinicalTrials.gov website, American Association of Pharmaceutical Scientists (AAPS), Eurostat, Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan CRO Association, Chinese Association for Laboratory Animal Sciences (CALAS), and Indian Society for Clinical Research (ISCR). Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global CRO services market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global CRO services market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from Tier 1 and Tier 2 companies engaged in offering services) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Contract Research Organization (CRO) Services Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the CRO services market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the CRO services business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Report Objectives

  • To define, describe, and forecast the contract research organization (CRO) services market based on type, therapeutic area, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (drivers, opportunities, and challenges) along with the current trends
  • To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the revenue of market segments with respect to five major regions:
  • North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments in the CRO services market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and research & development activities  

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Report Code
PH 4672
Published ON
Feb, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Contract Research Organization (CRO) Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback